Glycostem is going to present a poster at the SITC 37th Annual Meeting, held November 10-12, 2022,  in Boston, MA, USA.

Title: Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia

Abstract Number: 245

Presentation and Session Information*
Annual Meeting Regular Poster Abstract Presenter:    (245) Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia
    Poster Hall
    11/10/2022 - 11/11/2022, 9:00 am - 9:00 pm

Presented by: Monica Raimo

Glycostem CDO Volker Huppert will be speaking at Cell Series UK conference on 7^th - 8^th November, 2022.

Glycostem CEO Troels Jordansen will present at the Onco Cell Therapy Summit Europe taken place on 2^nd-3^rd Nov 2022 in Amsterdam.

Date and time: 2^nd Nov 2022 11:00 (CET)
Presentation title: Developing end-to-end, closed manufacturing of NK cell therapy from umbilical cord blood (UCB)- derived stem cells
• Set-up of production and implementing automation
• Exploration of how this process can reduce investment

Glycostem CDO Volker Huppert and CMO Kai Pinkernell are going to present at the Innate Killer Summit Europe.

20^th Oct 2022 08:30 GMT+1, Volker Huppert:

Maximising Product Stability by Understanding Fundamental Elements of Stability to Advance Cryopreservation Protocols

20^th Oct 2022 14:30 GMT+1 Kai Pinkernell:

Bringing Allogeneic NK cells into Clinical Trials for AML

Glycostem to participate 22nd Annual Biotech in Europe Forum (BEF), in-person event on 21^st-22^nd of September 2022 at Basel, Switzerland.

Glycostem CEO Troels Jordansen and CMO Kai Pinkernell to present at the Advanced Therapies Europe, on 1^st Sep 2022 in the below sessions:

09:00 SPOTLIGHT ROUNDTABLES
ROUNDTABLE 6: PATIENT ENGAGEMENT DURING CLINICAL DEVELOPMENT: KEEPING THE ‘CUSTOMER’ IN MIND 
Moderator: Kai Pinkernell, Chief Medical Officer, Glycostem

13:55 – CASE STUDY: OPTIMISING FACILITY & LOCATION FOR CANCER CARE
Speaker: Troels Jordansen, CEO, Glycostem Therapeutics